UBS upgraded Jazz Pharmaceuticals (JAZZ) to Buy from Neutral with a price target of $179, up from $145. The company’s base business strength ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback